Course and Correlates of Stigma in Patients on Opioid Agonist Treatment: A Prospective Study from an Outpatient Treatment Program in India

被引:1
作者
Ghosh, Abhishek [1 ]
Roub, Fazle [1 ]
Pillai, Renjith R. [1 ]
Mahintamani, Tathagata [1 ]
Basu, Debasish [1 ]
Subodh, B. N. [1 ]
Mattoo, S. K. [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Drug Deaddict & Treatment Ctr, Dept Psychiat, Sect 12, Chandigarh 160012, India
关键词
Buprenorphine; enacted stigma; internalized stigma; opioid dependence; quality of life; SUBSTANCE USE DISORDERS; INTERNALIZED STIGMA; MENTAL-ILLNESS; SELF-STIGMA; INDIVIDUALS; QUALITY; SCALE; ABUSE; MODEL; LIFE;
D O I
10.1177/02537176211012103
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Individuals with opioid dependence experience stigma and discrimination. Stigma can potentially reduce treatment-seeking and negatively affect treatment outcomes. We aimed to study the course of stigma and its correlates among patients receiving opioid agonist treatment (OAT). Methods: We recruited 51 subjects (aged between 18 and 45 years) registered in the OAT clinic from February to September 2019. We excluded subjects dependent on alcohol and other drugs (except for cannabis and tobacco), with severe mental illness, intellectual disability, and organic brain disease. We assessed the internalized and enacted stigma and quality of life at the treatment entry and after 3 months. Relationship of stigma with quality of life, socio-demographic, and other clinical variables were examined at the treatment entry. Results: Mean age of the subjects was 26.7 (+/- 5) years. At the end of three months, 33 (64.7%) patients were retained in the treatment. Internalized stigma correlated negatively with the social and environmental domains of quality of life. The strength of the correlations was modest. No significant correlation was found between demographic and clinical variables and internalized stigma and enacted stigma scores. Both internalized and enacted stigma scores reduced significantly at 3 months follow-up. The significance levels were retained even after controlling for the baseline quality of life scores. Stigma at the treatment entry did not predict early dropout. Conclusion: Despite higher severity at the treatment entry, the level of internalized and enacted stigma reduced significantly within three months of an outpatient-based OAT program.
引用
收藏
页码:246 / 252
页数:7
相关论文
共 50 条
  • [31] Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder
    Thakrar, Ashish P.
    Uritsky, Tanya J.
    Christopher, Cara
    Winston, Anna
    Ronning, Kaitlin
    Sigueza, Anna Lee
    Caputo, Anne
    McFadden, Rachel
    Olenik, Jennifer M.
    Perrone, Jeanmarie
    Delgado, M. Kit
    Lowenstein, Margaret
    Compton, Peggy
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2023, 18 (01)
  • [32] HIV Treatment Outcomes Among HIV-Infected, Opioid-Dependent Patients Receiving Buprenorphine/Naloxone Treatment within HIV Clinical Care Settings: Results From a Multisite Study
    Altice, Frederick L.
    Bruce, R. Douglas
    Lucas, Gregory M.
    Lum, Paula J.
    Korthuis, P. Todd
    Flanigan, Timothy P.
    Cunningham, Chinazo O.
    Sullivan, Lynn E.
    Vergara-Rodriguez, Pamela
    Fiellin, David A.
    Cajina, Adan
    Botsko, Michael
    Nandi, Vijay
    Gourevitch, Marc N.
    Finkelstein, Ruth
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 56 : S22 - S32
  • [33] Desirable treatment or a problematic drug scene? - An interview study of patients' and professionals' views on the risks and benefits of liberalized opioid agonist treatment
    Nordgren, Johan
    Richert, Torkel
    [J]. HARM REDUCTION JOURNAL, 2025, 22 (01)
  • [34] Associations Between Opioid Agonist Treatment and Withdrawal Symptoms: Exploratory Analyses from the OPTIMA Study
    Bakouni, Hamzah
    Elkrief, Laurent
    Bijou-Coulon, Sabrina
    Socias, Maria Eugenia
    Le Foll, Bernard
    Lim, Ron
    Jutras-Aswad, Didier
    [J]. CANADIAN JOURNAL OF ADDICTION, 2024, 15 (01) : 6 - 15
  • [35] Exploring dual diagnosis in opioid agonist treatment patients: a registry-linkage study in Czechia and Norway
    Rolova, Gabriela
    Skurtveit, Svetlana
    Gabrhelik, Roman
    Mravcik, Viktor
    Odsbu, Ingvild
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2024, 19 (01):
  • [36] A parenting education program for women in treatment for opioid-use disorder at an outpatient medical practice
    Kahn, Linda S.
    Mendel, Whitney E.
    Fallin, Kyla L.
    Borngraber, Elizabeth A.
    Nochajski, Thomas H.
    Rea, William E.
    Blondell, Richard D.
    [J]. SOCIAL WORK IN HEALTH CARE, 2017, 56 (07) : 649 - 665
  • [37] Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study
    Sanvisens, Arantza
    Rivas, Inmaculada
    Faure, Eva
    Espinach, Nestor
    Hernandez-Rubio, Anna
    Majo, Xavier
    Colom, Joan
    Muga, Robert
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (38) : 5874 - 5883
  • [38] Quality of Life Profiles and Changes in the Course of Maintenance Treatment Among 1,015 Patients With Severe Opioid Dependence
    Karow, A.
    Verthein, U.
    Pukrop, R.
    Reimer, J.
    Haasen, C.
    Krausz, M.
    Schaefer, I.
    [J]. SUBSTANCE USE & MISUSE, 2011, 46 (06) : 705 - 715
  • [39] Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study
    Anna Conway
    Alison D. Marshall
    Sione Crawford
    Jeremy Hayllar
    Jason Grebely
    Carla Treloar
    [J]. Implementation Science, 18
  • [40] Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study
    Conway, Anna
    Marshall, Alison D.
    Crawford, Sione
    Hayllar, Jeremy
    Grebely, Jason
    Treloar, Carla
    [J]. IMPLEMENTATION SCIENCE, 2023, 18 (01)